Use of CDK9 inhibitors to reduce cartilage degradation

摘要

The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.

主权项

1. A method of reducing or inhibiting cartilage degradation and/or chondrocyte death in a subject who has experienced a traumatic joint injury, comprising administering to the subject an effective amount of flavopiridol or an analog or salt thereof, wherein the traumatic joint injury triggers an acute cellular response characterized by the release of inflammatory mediators from the injured joint tissues, wherein the flavopiridol or analog or salt thereof is initially administered within 4 days after experiencing the traumatic joint injury, thereby reducing or inhibiting cartilage degradation and/or chondrocyte death in the subject.